跳至主要内容
临床试验/NCT00185094
NCT00185094已完成4 期

The Effects of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on Insulin Sensitivity in Overweight and Obese Subjects With Hypertension

Daiichi Sankyo10 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2004年2月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
60
试验地点
10
主要终点
To compare the treatment effect of olmesartan medoxomil versus that of atenolol on insulin sensitivity

研究概览

简要总结

To examine the effect of three different blood pressure medications on the insulin sensitivity in overweight patients with high blood pressure.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients between the ages of 18 and 75 years (inclusive)
  • Willingness to undergo insulin clamp procedure twice
  • Overweight or obese (BMI=25-39 kg/m2)
  • Subject must meet one of the following two blood pressure criteria at week-2 and at week-1: Systolic blood pressure 140-179 mmHg and diastolic blood pressure 85-99 mmHg OR Systolic blood pressure < 140 mmHg and diastolic blood pressure 90-99 mmHg
  • If female, must have negative serum pregnancy test at screening and be either post-menopausal, had a hysterectomy or tubal ligation at least 6 months before consent or if of childbearing potential, must practice approved measures of birth control throughout study

排除标准

  • Systolic blood pressure > 179 mmHg
  • Diastolic blood pressure > 99 mmHg or < 85 mmHg
  • Diagnosis of diabetes mellitus
  • History of myocardial infraction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, unstable angina pectoris or an episode of heart failure requiring hospitalization
  • Previous history of a cerebrovascular accident or a transient ischemic attack
  • History of allergic response to atenolol, losartan potassium, olmesartan medoxomil or any of their components
  • Any serious disorder, including pulmonary, hepatic, renal, gastrointestinal (including clinically significant malabsorption), uncontrolled endocrine/metabolic, hematologic/oncologic (within the last 5 years), neurologic, and psychiatric diseases, that would interfere with the conduct of the study or interpretation of the data
  • Laboratory abnormalities that could compromise subject safety

结局指标

主要结局

To compare the treatment effect of olmesartan medoxomil versus that of atenolol on insulin sensitivity

次要结局

  • -To compare the treatment effect of losartan potassium versus atenolol on insulin sensitivity
  • -To compare the treatment effect of olmesartan medoxomil versus losartan potassium on insulin sensitivity

研究者

申办方类型
Industry

研究点 (10)

Loading locations...

相似试验